Replies to post #46433 on MultiCell Technologies Inc (MCET)

[Mcetdreamer]

This article might help you decide if MCET is a stock for you? It gives a opinion from both sides. Please do your own DD.

More to come.


LaptrinhX / News
MICROCAPDAILY.COM MEDIA TECHNOLOGY MICRO CAP INSIDER SMALL CAPS MCETBiotech Sleeper MCET (MultiCell Technologies) Surging Higher as its Fa N2-4 immortalized Human Hepatocytes Cell Lines Patent Gains Traction9 Min Read1 Month Ago

Biotech Sleeper MCET (MultiCell Technologies) Surging Higher as its Fa N2-4 immortalized Human Hepatocytes Cell Lines Patent Gains Traction
MCET (MultiCell Technologies) has been heating up and running northbound in recent weeks running out of the triple zeroes and trading several hundred million shares a day with a recent high of $0.0016 per share. The stock has been under heavy accumulation recently and volume has picked up substantially as a new era of penny stock speculators fueled by robinhood and its 100 million new trading accounts take on the bulletin boards. These are different times than just a few short years ago; now penny stocks such as TSNP can achieve a $6 billion plus market valuation and trade $375 million in dollar volume in a day on the bulletin boards. And TSNP has no stronger fundamentals than MCET has.

Investors are cautious in MCET as the Company is pink no information on OTCMarkets and has not put out a filing or a press release in years. MCET once owned a very valuable patent portfolio however many of these patents were lost due to the Company not filing the mandatory maintenance fee at 4, 8 and at twelve years after the U. S. Patent office granted them patents. However, the Company does still own a number of valuable patents that we know of for sure including the Fa N2-4 immortalized Human Hepatocytes Cell Lines. Recently, David Lewis paid the Patent maintenance fee on the Fa N2-4 immortalized Human Hepatocytes Cell Lines. Back in 2009 MCET was granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines. The Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines were derived from normal human liver cells, and are nontumorigenic, stable in culture, and produce therapeutic plasma proteins in cell culture. The Fa2N-4 cell line has also been engineered to function as a proxy for normal human liver cells for use in performing drug toxicity assays. MultiCell has licensed several pharmaceutical companies’ rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals. There is a growing movement of shareholders led by Mcetdreamer who contend the Fa N2-4 immortalized Human Hepatocytes Cell Lines patent is currently being infringed upon by a number of Company’s and MCET management has done nothing about it; Barbara Newman wrote at one point she “didn’t know what they can do about it.”

MCET (MultiCell Technologies) is a biopharmaceutical company developing therapeutic candidates based on modulation of the immune system plus new antiviral treatments to address influenza and other infectious diseases. (Microcapdaily would like to make it clear this information is years old) MultiCell produces cell lines used by pharmaceutical companies to screen and develop new drugs and therapeutics. The Company owns a majority interest in its two subsidiary companies MultiCell Immunotherapeutics, Inc. (MCTI) of which MultiCell holds 85.1% of the outstanding shares and Xenogenics of which MultiCell holds 95.3% of the outstanding shares.

It is not exactly certain who is currently in charge of the Company; it could be the Company’s old CEO Jerry Newmin who is now close to 80 years old or his wife Barbara or the Company’s director, Ed Sigmond; a Partner at Sigmond & Johnson, Inc. Mr. Sigmond was also President at Kestrel Holdings, Inc., Chairman, CEO & Head-Investor Relations at The Great American Food Chain, Inc., Managing Partner & Owner at The Elbow Room, and a Director & Partner at Na Zdravi Ventures. He is/was on the Board of Directors at MultiCell Technologies, Inc.

Back when MultiCell was more active the Company described itself as: (this information is years old and much of its may no longer be valid) MultiCell is the vendor of two lines of immortalized human hepatocytes to the pharmaceutical and biotech industries. These progenitor cells and immortalized liver cells have been validated for use in drug discovery by XenoTech, Pfizer and Bristol Meyers Squibb.

MultiCell’s immortalized human hepatocyte lines closely resemble primary human liver cells in morphology and function. Hepatocytes express drug-metabolizing enzymes that biotransform drugs or substances ingested into the body, so they help predict the effect of a compound on human livers. MultiCell’s cell lines are sensitive to compounds that increase the expression of CYP3A4, an essential feature of in vitro model systems when studying drug-drug interactions. They eliminate the problem of limited supply and organ donor variability that restrict the use of harvested human liver cells for enzyme induction, cellular toxicity assays and other in vitro screening. The bio-reactivity of MultiCell’s cell lines may save years of time and millions of dollars during pre-clinical drug discovery, development and testing stages. Hepatocytes metabolize or de-toxify drugs or substances ingested into the body. Drug failures or FDA rejections due to hepatotoxicity and/or drug-drug interactions now cost the pharmaceutical industry an estimated $2 billion each year. It costs about $900 million to develop and test a new medicine.

MultiCell also has intellectual property in the area of drug discovery and stem cells and the patented Sybiol(TM) synthetic bio-liver therapeutic liver assist device. MultiCell holds two patents on novel strategies for isolation of adult human liver cells, and cell clusters or doublets, invented by Dr. Ronald A. Faris, Senior Vice President and Chief Scientific Officer of MutliCell and Director of Research with Rhode Island Hospital. Obtaining stem cells from adult tissues avoids the ethical issues and the contamination issues associated with embryonic or fetal stem cells. Liver stem cells may play a key role in transplantation for tissue regeneration and therapeutic use including the clinical management of metabolic liver disorders and heart disease as well as potential diagnostic applications. The use of liver stem cells to treat diseases, such as Hepatitis C, may greatly enhance quality of life and avoid costly whole organ liver transplantation. MultiCell believes its patented stem cell techniques are unique within the cell therapy market.

The Companys subsidiary XenoTech was founded by Andrew Parkinson, Ph.D. to study drug metabolism and safety. XenoTech provides products and contract research services to pharmaceutical companies throughout the world to optimize discovery, development and approval of new drugs. XenoTech’s products and services, including MultiCell’s hepatocytes, are marketed in Japan by Nosan Corporation and by tebu-bio in Europe. (this information is years old and much of its may no longer be valid)

Investor sentiment is very high:

$MCET This is the last super cheap bio tech out there but wont be for long IMO.

— william payne (@Fastmoneylong) February 15, 2021

@AngryRed316 I’m try to be helpful for once…check out $MCET

— Mt. Goals (@mt_goals) February 10, 2021

To Find out the inside Scoop on MCET Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

MCET

MCET once owned a very valuable patent portfolio however many of these patents were lost due to the Company not filing the mandatory maintenance fee at 4, 8 and at twelve years after the U. S. Patent office granted them patents. However, the Company does still own a number of valuable patents that we know of for sure including the Fa N2-4 immortalized Human Hepatocytes Cell Lines. Recently, David Lewis paid the Patent maintenance fee on the Fa N2-4 immortalized Human Hepatocytes Cell Lines.

Back in 2009 MCET was granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines. The Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines were derived from normal human liver cells, and are nontumorigenic, stable in culture, and produce therapeutic plasma proteins in cell culture. The Fa2N-4 cell line has also been engineered to function as a proxy for normal human liver cells for use in performing drug toxicity assays. MultiCell has licensed several pharmaceutical companies’ rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals.

MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications as well as for drug adsorption, distribution, metabolism and excretion (ADME) studies. MultiCell retained worldwide exclusive ownership of the Fa2N-4 and Ea1C-35 cell lines for all applications other than ADME/Tox, including drug target identification and using the cell lines for the production of therapeutic plasma proteins.

There is a growing movement of shareholders led by Mcetdreamer who contend the Fa N2-4 immortalized Human Hepatocytes Cell Lines patent is currently being infringed upon by a number of Company’s and MCET management has done nothing about it; Barbara Newman wrote at one point she “didn’t know what they can do about it.”

The role of liver stem cells in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma in humans arises by maturation arrest of liver stem cells. Jerry Newmin, Chairman & CEO of MultiCell Technologies commented at the time of this release in 2009: “MultiCell intends to use its human liver cell and liver stem cell assets to identify therapeutic targets and new drug candidates specifically targeting the treatment of primary liver cancer and intrahepatic bile duct cancer. We believe our engineered human liver cell lines will play an important role as proxies for normal human liver cells in our effort to identify drug targets.”

The National Cancer Institute (NCI) in 2008 stated there were approximately 21,400 new cases of hepatocellular carcinoma and intrahepatic bile duct cancer in the United States, and approximately 18,400 of those cases resulted in death. Hepatocellular carcinoma, resulting from Hepatitis B and Hepatitis C infection, is the most common cancer in some parts of the world, with more than 1 million new cases diagnosed each year. The NCI also reports that hepatocellular carcinoma is associated with cirrhosis of the liver in 50% to 80% of patients.

$MCET

Getting in early is
??
Pay attention .001 and beyond incoming
??
https://t.co/dP31wnEIBXhttps://t.co/Qr29f9hSqV pic.twitter.com/oi43bw9f6Z

— Roid (@Roid23501178) January 22, 2021

Microcapdialy has written about MCET before. Back in 2015 we wrote of MCET: “MultiCell Technologies, Inc. (OTCMKTS:MCET) made a big move up today off its $0.0002 lows on massive volume. The move is a huge welcome to shareholders who have endured months of nothing since the run this one made in March 2014. The big move today came after MCET announced a research & development and product license agreement with Oxis Biotech to create three novel antibody-drug conjugates (ADCs) containing OXIS’ lead drug candidates using MCIT’s proprietary ADC platform technology. MultiCell Technologies, Inc. (OTCMKTS:MCET) is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease and cancer. MCET majority owned subsidiary is MultiCell Immunotherapeutics, a biotechnology company developing novel therapeutics and drug delivery platform technologies to treat a variety of human diseases. MCIT’s next-generation antibody drug conjugates provide for the simultaneous targeted delivery of multiple drugs from a single antibody. This unique, targeted co-delivery capability enables the localization of both drugs within a target cell where they exert their biological effect and helps to minimize adverse off-target effects.” MCET drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

For More on MCET Subscribe Right Now!

MCET has been heating up and running northbound in recent weeks running out of the triple zeroes and trading several hundred million shares a day with a recent high of $0.0016 per share. The stock has been under heavy accumulation recently and volume has picked up substantially as a new era of penny stock speculators fueled by robinhood and its 100 million new trading accounts take on the bulletin boards. These are different times than just a few short years ago; now penny stocks such as TSNP can achieve a $6 billion plus market valuation and trade $375 million in dollar volume in a day on the bulletin boards. And TSNP has no stronger fundamentals than MCET has. Investors are cautious in MCET as the Company is pink no information on OTCMarkets and has not put out a filing or a press release in years. MCET once owned a very valuable patent portfolio however many of these patents were lost due to the Company not filing the mandatory maintenance fee at 4, 8 and at twelve years after the U. S. Patent office granted them patents. However, the Company does still own a number of valuable patents that we know of for sure including the Fa N2-4 immortalized Human Hepatocytes Cell Lines. Recently, David Lewis paid the Patent maintenance fee on the Fa N2-4 immortalized Human Hepatocytes Cell Lines. Back in 2009 MCET was granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines. The Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines were derived from normal human liver cells, and are nontumorigenic, stable in culture, and produce therapeutic plasma proteins in cell culture. The Fa2N-4 cell line has also been engineered to function as a proxy for normal human liver cells for use in performing drug toxicity assays. MultiCell has licensed several pharmaceutical companies’ rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals. There is a growing movement of shareholders led by Mcetdreamer who contend the Fa N2-4 immortalized Human Hepatocytes Cell Lines patent is currently being infringed upon by a number of Company’s and MCET management has done nothing about it; Barbara Newman wrote at one point she “didn’t know what they can do about it.” We will be updating on MCET when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with MCET.

Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in MCET either long or short and we have not been compensated for this article. We were initially contacted by Mcetdreamer about MCET.

The post Biotech Sleeper MCET (MultiCell Technologies) Surging Higher as its Fa N2-4 immortalized Human Hepatocytes Cell Lines Patent Gains Traction first appeared on Micro Cap Daily.

Source: microcapdaily.com
Biotech Sleeper MCET (MultiCell Technologies) Surging Higher as its Fa N2-4 immortalized Human Hepatocytes Cell Lines Patent Gains Traction

LaptrinhX / News © 2021
https://laptrinhx.com/news/biotech-sleeper-mcet-multicell-technologies-surging-higher-as-its-fa-n2-4-immortalized-human-hepatocytes-cell-lines-patent-gains-traction-8dGMzlR/

[galingolin]

Very concise and to the point. Thank you, G

[Mcetdreamer]

I have been working
with Dan Brickman over the past month. Bouncing information back and forth. Dan posted the PowerPoint regarding MCET on Youtube...

Dan put together spreadsheets regarding:

How much stock MCET corporate officers owns per SEC Filings.

We now know what happened to all 34 patents that MCET and their subsidiaries owned, and this includes any of the exclusive rights MCET owns.

We also know how many patents are still current and in what county? It's criminal what happened to some of these Patents. Because they still are being used today.

He also put together all the SEC filings on one spreadsheet.

Dan did a lot of the work on the YouTube PowerPoint. If you get a chance to see it. There is a lot of good information on it

Please click on the link below:

We could have added more, but until we get more documented. We need to wait.

Bottom line, Dan is a great asset to have on your side.

He offered to work with
MCET to build them a website and being current the missing SEC filing.

It's really nice to be part of this.

It's also funny why Fiberman hasn't tore apart any of our research.

It's because he can't. The only thing he pointed out was, the stock Dr Chang didn't buy in 2020